Journal of Cardiac Failure
Volume 14, Issue 4 , Pages 303-309, May 2008

Inpatient Initiation of β-blockade Plus Nurse Management in Vulnerable Heart Failure Patients: A Randomized Study

  • Mori J. Krantz, MD

      Affiliations

    • Department of Medicine, Cardiology Division at Denver Health Medical Center and the University of Colorado Health Sciences Center
    • Colorado Prevention Center, Denver, Colorado
    • Corresponding Author InformationReprint requests: Mori J. Krantz, MD, Denver Health Medical Center, Mail Code 0960, 777 Bannock Street, Denver CO 80204-4507.
  • ,
  • Edward P. Havranek, MD

      Affiliations

    • Department of Medicine, Cardiology Division at Denver Health Medical Center and the University of Colorado Health Sciences Center
    • Colorado Prevention Center, Denver, Colorado
  • ,
  • Deborah K. Haynes, RN BScN

      Affiliations

    • Department of Medicine, Cardiology Division at Denver Health Medical Center and the University of Colorado Health Sciences Center
    • Colorado Prevention Center, Denver, Colorado
  • ,
  • Inez Smith, RN, BAN

      Affiliations

    • Department of Medicine, Cardiology Division at Denver Health Medical Center and the University of Colorado Health Sciences Center
    • Colorado Prevention Center, Denver, Colorado
  • ,
  • Becki Bucher-Bartelson, PhD

      Affiliations

    • Colorado Prevention Center, Denver, Colorado
  • ,
  • Carlin S. Long, MD

      Affiliations

    • Department of Medicine, Cardiology Division at Denver Health Medical Center and the University of Colorado Health Sciences Center
    • Colorado Prevention Center, Denver, Colorado

Received 26 November 2007; received in revised form 17 December 2007; accepted 18 December 2007. published online 07 April 2008.

Abstract 

Background

Predischarge β-blocker initiation in hospitalized patients with heart failure due to reduced left ventricular ejection fraction (LVEF) is safe and improves adherence; improved outcomes with this approach have not been demonstrated in a randomized trial. This study compared 6-month rehospitalization rates among patients assigned to predischarge β-blockade coupled with postdischarge nurse management (intervention) versus usual care.

Methods and Results

We randomized 64 patients with an LVEF ≤0.40 to low-dose carvedilol coupled with nurse management or usual care. The nurse manager saw patients within 2 weeks of discharge, then biweekly until stable. Baseline characteristics reflected a vulnerable population (80% uninsured, 72% minorities, 80% unemployed or disabled), as did heart failure etiology (28% substance abuse, 27% ischemic, 19% hypertension, 17% idiopathic). Mean baseline LVEF was 0.23 in both groups. Among intervention patients at 6 -months, β-blocker utilization was higher (96 vs. 48%, P < .001), mean New York Heart Association class improved (–1.44 vs. –0.77, P = .01), and total heart failure rehospitalizations were reduced by 84% (3 vs. 19, P = .02). A trend toward improved LVEF was also observed (+16 vs. +11 units, P = .17).

Conclusion

Inpatient β-blocker initiation coupled with nurse management improved outcomes among sociodemographically disadvantaged heart failure patients. Our results support a practice shift toward inpatient β-blocker initiation with structured outpatient follow-up.

Key Words: Carvedilol, disease management, hospitalization, guidelines

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 MK and CSL report having received consulting fees from GlaxoSmithKline and AstraZeneca.

 The trial was an investigator initiated study funded by Glaxo Smith Kline; Philadelphia, PA. The sponsor had no role in the conception, design, or implementation of the trial. Interpretation and analysis of all data were done solely by the clinical investigators. Clinicaltrials.gov identifier: NCT00381030.

PII: S1071-9164(07)01167-0

doi:10.1016/j.cardfail.2007.12.008

Journal of Cardiac Failure
Volume 14, Issue 4 , Pages 303-309, May 2008